May Kazem, MD MHA FRCPC retweeted
Obesity Journal Club nitter.cf/i/broadcasts/1RKjpbAPE…
Patient-reported satisfaction following a switch from reference denosumab to biosimilar denosumab: real-world data from a Canadian patient survey tandfonline.com/doi/full/10.…
58
May Kazem, MD MHA FRCPC retweeted
A Tribute to Thomas A. Medsger Jr., MD (1936–2026)
The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.
buff.ly/Tt3pB2K
May Kazem, MD MHA FRCPC retweeted
EU Finalizes Tavneos Withdrawal - The European Commission has officially revoked the marketing authorization for Tavneos (avacopan), finalizing a process that began with regulators flagging the drug's pivotal trial data as "incorrect and misleading." The EC issued its legally binding decision on August 4, 2026, confirming a recommendation from the European Medicines Agency's human medicines committee (CHMP) that had been building since earlier this year americanpharmaceuticalreview…
May Kazem, MD MHA FRCPC retweeted
JAMA has updated its guidance for the acceptable use of AI in authoring a Medical Publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. This is about what is permitted & not permitted & what needs to be disclosed. jamanetwork.com/journals/jam…
May Kazem, MD MHA FRCPC retweeted
A Tribute to Daniel L. Kastner, MD, PhD (1951–2026)
The rheumatology, genetics and NIH communities mourn for Dr. Daniel L. Kastner, who died on July 28, 2026, in Bethesda, Maryland, at age 74.
buff.ly/RyPizbJ
May Kazem, MD MHA FRCPC retweeted
🆕 Gout Part 1: In Collaboration with @RheumNow
*Approach to Diagnosis & Management*
🧪Serologic Studies
🩻 Imaging Modalities: XR, US, DECT
🔬 Understanding Polarized Microscopy
#Gout #RheumX #RheumTwitter
May Kazem, MD MHA FRCPC retweeted
🆕 Visual Abstract with @HealioRheum 🟢
Bone Marrow Edema (BME) in the General Population
💡Key Takeaway: BME is NON-specific, and was seen in up to *30%* of healthy people (N >11,000)
📝 Bressem et al, Lancet Rheum
🔗: tinyurl.com/BMEHealio
#Rheumatology #RheumX #Radiology
May Kazem, MD MHA FRCPC retweeted
💡Listen to @JuliePaikMD discuss the VALOR Trial of brepocitinib in DM in this ACR on Air Podcast with @hausmannMD
🎧: tinyurl.com/myositispod
1st half ⇢ review of myositis
2nd half ⇢ discussion of the VALOR Trial
May Kazem, MD MHA FRCPC retweeted
🆕 Phase 3 RCT of #Brepocitinib (TYK2-JAK1 inhibitor) vs PBO in #Dermatomyositis (The VALOR Trial) 🔥
⌛ Rapid onset: improvements as early as wk 4
💪 All pts had both active muscle + skin disease
📈 Improvement in myositis activity, GC tapering
#Myositis #Rheumatology #DermX
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
@RheumNow
1
91
May Kazem, MD MHA FRCPC retweeted
Genicular artery embolization (GAE) in knee OA? Multiple open label studies & metanalyses suggest a clear pain benefit; BUT 3 sham-controlled RCTs have not demonstrated a statistically significant benefit over placebo. GAE is not addressed by ACR or EULAR guidelines. buff.ly/ljunvUv buff.ly/7uNdzzG
May Kazem, MD MHA FRCPC retweeted
DAY 1 & 2 Recap: EULAR 2026 Highlights nitter.cf/i/broadcasts/1rGmqqjYz…
May Kazem, MD MHA FRCPC retweeted
DAY 3 Recap: EULAR 2026 Highlights nitter.cf/i/broadcasts/1nKOLLmdR…
May Kazem, MD MHA FRCPC retweeted
DAY 4 Recap: EULAR 2026 Highlights nitter.cf/i/broadcasts/1XxyggMkb…
May Kazem, MD MHA FRCPC retweeted
#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort:
-enriched in Black patients
-poor response to B-cell depletion inc. Obi
-non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab
-High ferritin = flare @RheumNow
May Kazem, MD MHA FRCPC retweeted
#EULAR2026 OP0126 Long-term extension study up to 108 weeks: Ianalumab demonstrated sustained efficacy (change in ESSDAI) including those who switched from PBO to IAN in #Sjogren. IAN improved most domains apart from lungs, MSK & Haem - important to note @RheumNow #EULARBest
May Kazem, MD MHA FRCPC retweeted
#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval
@RheumNow #EULARBest
May Kazem, MD MHA FRCPC retweeted
#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk:
-VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile)
-No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest
May Kazem, MD MHA FRCPC retweeted
RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA
-Primary endpoint DAS28-CRP change wk12
-2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01
-ACR20/50/70 + CDAI LDA all improved vs PBO
-hsCRP reduction across all dose arms
-69% CDAI LDA by wk14
-wk 28 extension shows maintenance during off-drug follow-up
-Favourable safety profile
#OP0203 #EULAR2026 @RheumNow





















